E815
TEAS SECTION 8 & 15 RECEIVED
04/08/2026
Voltar para busca
Dado oficial do USPTO
BIOHAVEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
67
Atualização mais recente
04/08/2026
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
08/02/2017
Data de registro
18/08/2020
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
18/08/2020
Última transação
04/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
13/03/2020
Primeiro uso no comércio
13/03/2020
Código do desenho
4
Tipo de titular
99
Localização do titular
Road Town, Tortola, VG
Examinador
MAJCHER HARTNETT, MEGAN K
Unidade examinadora
N50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
BIOHAVEN THERAPEUTICS LTD.
Biohaven Pharmaceutical Holding Company Limited
Representantes
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicated and pharmaceutical preparationsboth prescription and over-the-counterfor use in connection with humans and animalsfor the treatment of central nervous system disordersneurologic illnessespsychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemiapost-stroke recoverysevere intracranial atherosclerosiscarotid endarterectomycardiac bypasscerebral vasculitisreversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuriespost- intracranial hemorrhage recoverytraumatic brain injuryspinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseasesAlzheimer's disease (AD)Amyotrophic Lateral Sclerosis (ALS)Huntington's diseaseLewy body dementiafrontotemporal dementiavascular dementiaParkinson's diseasecognitive impairment of agingprogressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathiesglaucomadiabetic retinopathyischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of painopioid sparing analgesiacancer painchronic neuropathic painperipheral neuropathylow back pain in the nature of failed back surgery syndromeradiculopathy in the nature of sciaticadiabetic peripheral neuropathypost-herpetic neuralgiachemotherapy induced neuropathy and other medication induced neuropathiescomplex regional pain syndromefibromyalgiachronic post-operative paincluster thoracotomyphantom limbstump neuroma; pharmaceutical preparations for the treatment of headache and facial painheadachemigrainechronic daily headachecluster headachetrigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseasesbreath holding in Rett syndromedystoniasdysphagiagait abnormalitiesbulbar function in ALSpseudobulbar affectlevodopa-induced dyskinesias in Parkinson's diseaseagitation in ADdisinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsyprecision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorderstreatment resistant depressionPost Traumatic Stress Disorder (PTSD) in the nature of hyperarousalsubstance abuse disordersaddiction disordersObsessive Compulsive Disorder (OCD)hoardingtrichotillomaniaeating disordersGeneralized Anxiety Disorder (GAD)adjustment disorderspanic disordermajor depressive episodebipolar disorder in the nature of manic and depressive episodesdysthymiacyclothymiapsychotic disordersschizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disordersspinocerebellar ataxiaFriedriech's ataxiamultisystem atrophyessential tremor; pharmaceutical preparations for the treatment of hearing disorderstinnitusdeliriumsleep disordersparasomniaslearning disordersAttention Deficit Disorder (ADD)Pervasive Developmental Disorders (PDD)Asperger's syndromeautismmenopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancermonotherapy and adjunctive use
Publicações
Histórico de despachos e eventos da marca no USPTO.
67 publicações encontradas
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
18/08/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/04/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/04/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/04/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/04/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
17/04/2023
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
11/01/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
21/06/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/06/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/06/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/06/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
21/06/2021
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
26/08/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
18/08/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
16/07/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
15/07/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
25/06/2020
IUAF
USE AMENDMENT FILED
23/06/2020
EISU
TEAS STATEMENT OF USE RECEIVED
23/06/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
14/05/2020
EX4G
SOU EXTENSION 4 GRANTED
13/05/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
13/05/2020
EXT4
SOU EXTENSION 4 FILED
01/05/2020
EEXT
SOU TEAS EXTENSION RECEIVED
01/05/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/02/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/02/2020
WOAG
WITHDRAWAL OF ATTORNEY GRANTED
13/01/2020
WOAR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
13/01/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
25/10/2019
EX3G
SOU EXTENSION 3 GRANTED
23/10/2019
EXT3
SOU EXTENSION 3 FILED
23/10/2019
EEXT
SOU TEAS EXTENSION RECEIVED
23/10/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
23/10/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
23/10/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
26/04/2019
EX2G
SOU EXTENSION 2 GRANTED
24/04/2019
EXT2
SOU EXTENSION 2 FILED
24/04/2019
EEXT
SOU TEAS EXTENSION RECEIVED
24/04/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/09/2018
EX1G
SOU EXTENSION 1 GRANTED
10/09/2018
EXT1
SOU EXTENSION 1 FILED
10/09/2018
EEXT
SOU TEAS EXTENSION RECEIVED
10/09/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
01/05/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/03/2018
PUBO
PUBLISHED FOR OPPOSITION
06/03/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/02/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/02/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/01/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/01/2018
ALIE
ASSIGNED TO LIE
26/01/2018
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
16/01/2018
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
08/01/2018
GNFR
FINAL REFUSAL E-MAILED
08/01/2018
CNFR
FINAL REFUSAL WRITTEN
08/01/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/12/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/12/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/12/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
21/06/2017
GNRT
NON-FINAL ACTION E-MAILED
21/06/2017
CNRT
NON-FINAL ACTION WRITTEN
21/06/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/05/2017
GNRT
NON-FINAL ACTION E-MAILED
09/05/2017
CNRT
NON-FINAL ACTION WRITTEN
09/05/2017
DOCK
ASSIGNED TO EXAMINER
03/05/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/02/2017
NWAP
NEW APPLICATION ENTERED
13/02/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BIOHAVEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.